INS and Hypoglycemia: Specifically, the proportion of patients that achieved HbA1c levels <7.0% without developing clinically significant or severe hypoglycemia events was higher in patients receiving insulin icodec rather than those receiving glargine U100, and improved Time in Range (TIR) results were observed both in icodec insulin-naïve patients and in those who switched from other basal insulins [32,33].